Computer-aided drug design (CADD) is one of the pivotal approaches to contemporary pre-
clinical drug discovery, and various computational techniques and software programs are …

Abstract Olmutinib (HM61713, OMT), a novel third-generation tyrosine kinase inhibitor with
good orally absorption, is able to inhibit selectively epidermal growth factor receptor …

Abstract Baricitinib is a Janus Kinase (JAK) inhibitor that is primarily used to treat moderately
to severely active rheumatoid arthritis in adults and has recently been reported for the …

Baricitinib (BRT) is an orally administered small molecule JAK inhibitor, which mainly
inhibits JAK-1 and JAK-2. And it is used to treat autoimmune diseases such as rheumatoid …

9-Hydroxyphenanthrene (9-OHPhe), the representative hydroxyl metabolite of
phenanthrene, has generated increasing concern as it is potentially hazardous to …

Co-administration of two drugs to obtain a therapeutic goal is a common practice clinically
and for effective use of drug therapy. However, the co-administration can sometimes cause …

Entrectinib (ENB), a novel potent tyrosine kinase inhibitor, has demonstrated promising
activity against specific genetic alterations in various solid tumors. Investigating the …

The competition among drugs for binding to plasma proteins is regarded as a
pharmacokinetic drug interaction. Competition between antitumor agents and other drugs for …

In the present work, the interactions of astragalin (AST) with human serum albumin (HSA)
were studied systematically thought fluorescence spectra, ultraviolet-visible (UV-vis) …

Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor tyrosine kinase member of the
TEC family of tyrosine kinases. Pre-clinical and clinical data have shown that targeting BTK …